GSK Lotronex Risk Management Program Allows For Off-Label Use
Executive Summary
GlaxoSmithKline will track prescriptions for Lotronex to gauge use of the irritable bowel syndrome therapy outside of the risk management program
You may also be interested in...
Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows
Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows
FDA Office Of Drug Safety Director-Designate Is ODE III Deputy Raczkowski
FDA Office of Drug Safety Director-designate Victor Raczkowski, MD, brings hands-on experience with the application of risk-management techniques from the review of GlaxoSmithKline's Lotronex